Neurofilaments as a biomarker for disease progression in MS

Using neurofilament proteins as biomarkers for disease progression in multiple sclerosis could become crucial in clinical practice.

Dr Sharmilee Gnanapavan has received consulting fees from Biogen, Genzyme, Teva and Novartis. She has also received travel support from Teva, Novartis, Genzyme, Biogen, National Multiple Sclerosis Society and MS Research Australia. Dr Sharmilee Gnanapavan has received grant support from the National Multiple Sclerosis Society, Genzyme, Takeda, Roche.